Skip to main content

Table 2 Cancer risk compared with the general population and relative risk in the TNFi-exposed vs biologic naïve participants

From: Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

 

Risk in biologic-naïve RA patients

Risk in TNFi-exposed patients

TNFi-exposed vs biologic-naïve patients

Observed

Expected

SIR* (95% CI)

Observed

Expected

SIR (95% CI)

RR (95% CI)

All invasive cancers

49

32.27

1.52 (1.16, 2.02)

107

102.62

1.04 (0.87, 1.27)

0.71 (0.46, 1.08)

Melanoma

4

2.65

1.51 (0.57, 5.35)

12

9.17

1.31 (0.76, 2.46)

1.18 (0.29, 4.70)

Lung

9

3.35

2.69 (1.43, 5.68)

16

9.45

1.69 (1.05, 2.90)

0.38 (0.12, 1.20)

Lymphoid cancers

5

2.71

1.84 (0.78, 5.47)

15

8.24

1.82 (1.12, 3.18)

0.79 (0.25, 2.55

Bowel

7

4.59

1.53 (0.74, 3.66)

10

13.11

0.76 (0.42, 1.54)

0.75 (0.17, 3.29)

Prostate

10

4.75

2.10 (1.18, 4.12)

12

13.67

0.88 (0.51, 1.64)

0.67 (0.23, 1.99)

Breast

8

4.58

1.75 (0.90, 3.86)

17

19.35

0.88 (0.56, 1.47)

0.50 (0.22, 1.16)

  1. SIR Standardised Incidence Ratio, CI confidence interval, RR relative risk